Revefenacin: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;"></span></i> Life-threatening meningococcal infections/sepsis | |blackBoxWarningBody=<i><span style="color:#FF0000;"></span></i> Life-threatening meningococcal infections/sepsis | ||
*Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies | *Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies | ||
*Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of | *Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risks of developing a meningococcal infection | ||
*Vaccination reduces, but does not eliminate, the risk of meningococcal infection | *Vaccination reduces, but does not eliminate, the risk of meningococcal infection | ||
** Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected | ** Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected | ||
ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ULTOMIRIS REMS, prescribers must enroll in the program | |||
Enrollment in the | Enrollment in the ULTOMIRIS REMS program and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com. | ||
|fdaLIADAdult= | |||
==Dosage== | ==Dosage== |
Revision as of 04:32, 9 October 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
|blackBoxWarningTitle= WARNING: SERIOUS MENINGOCOCCAL INFECTIONS |blackBoxWarningBody= Life-threatening meningococcal infections/sepsis
- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies
- Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risks of developing a meningococcal infection
- Vaccination reduces, but does not eliminate, the risk of meningococcal infection
- Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected
ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ULTOMIRIS REMS, prescribers must enroll in the program Enrollment in the ULTOMIRIS REMS program and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com.
|fdaLIADAdult=
Dosage
- The agreed dosage is 175 micrograms per day
- Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
- Makes it easy for patients with pulmonary problems
Contradictions
Hypersensitivity under any ingredient in Revefenacin
Warnings
See Adverse Reactions
Adverse Reactions
Side Effects
- Headache
- Cough
- Problems regarding the upper respiratory system
- Back Pain
Drug Interactions
- Revefenacin and active metabolite (when drug is metabolized by the body into a modified form) are not affected severely smoking status
Use in Specific Populations
- Revefencin is not affected majorly by age, weight, or gender
- Hepatic impariment has not been studied to see if there are necessary precautions to take
- Patients with renal impariment
- Mesure for antimuscarinic adverse events or the inhibitting of acetocholine, a neurotransmitter in the PNS
IV Compatibility
- Intravenous solution in healthy volunteers
- Volume of distribution was 218 L
- Intravenous solution radioactivity:
- 54% came out as solid waste
- 27% came out as liquid waste
Pharmacology
See Clinical Studies
Clinical Studies
Trials:
- Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
- 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)
Pharmacology trials:
- Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans
- Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs
- This drug attacked "mAChRs mediated contractile responses"
- This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans
Conclusion:
- Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD
How is it supplied
- Given to patients via jet nebulizer
Patient Counseling Information
- Currently Running a 52 week phase three trial for patients with severe OCPD
Precautions with Alcohol
There is limited information on Alcohol-Revefencin interactions. Talk to your doctor for further instruction on consuming alcohol with Revefenacin.
Brand Names
- Yupelri